In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
How to Find a Cancer Treatment Trial
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary
Featured Clinical Trials Supported by NCI

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 48 for your search:

Drug:  exemestane
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer

Phase: Phase IV
Type: Natural history/Epidemiology
Status: Enrolling by invitation
Age: Postmenopausal
Sponsor: Pharmaceutical / Industry
Protocol IDs: A5991089, NCT01047358

Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: Postmenopausal
Sponsor: NCI, Other
Protocol IDs: CDR0000456382, ACOSOG-Z1031, CALGB-ACOSOG-Z1031, SDC1, NCT00265759

Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast Cancer

Phase: Phase III
Type: Treatment
Status: Completed
Age: Postmenopausal
Sponsor: Other
Protocol IDs: EORTC-10951, PHARMACIA-EORTC-10951, NCT00002777

Phase III Randomized Study of Exemestane Versus Tamoxifen in Postmenopausal Women With Primary Breast Cancer Who Have Already Received 2-3 Years of Adjuvant Tamoxifen After Potentially Curable Surgery. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III
Type: Treatment
Status: Closed
Age: Postmenopausal
Sponsor:
Protocol IDs: ICCG-96OEXE031-C1396-BIG9702, EORTC-10967, FRE-FNCLCC-PACS02/96OEXE031, EU-20013, EU-99002, ICCG-BIG-97/02, NCT00003418

Phase III Randomized Study of Adjuvant Exemestane Versus Adjuvant Tamoxifen in Postmenopausal Women With Early Breast Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III
Type: Treatment
Status: Closed
Age: Any age
Sponsor: Other
Protocol IDs: CRC-TU-TEAM, EU-20149, ISRCTN75225940, NCT00032136

Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: Premenopausal
Sponsor: NCI, Other
Protocol IDs: CDR0000316456, IBCSG 24-02, BIG 2-02, CALGB-IBCSG 24-02, CAN-NCIC-IBCSG 24-02, NCCTG-IBCSG 24-02, NSABP-IBCSG 24-02, SWOG-IBCSG 24-02, NABCI-IBCSG 24-02, UCLA-0403024-01, EU-20334, EUDRACT-2004-000166-13, NCT00066690

Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: Premenopausal
Sponsor: NCI
Protocol IDs: NCI-2009-01087, IBCSG 25-02, CDR0000316458, N02CM62212, BIG-3-02, NABCI-IBCSG-25-02, EU-20347, EUDRACT-2004-000168-28, NCT00066703

Suppression of Ovarian Function and Either Tamoxifen or Exemestane With or Without Chemotherapy in Treating Premenopausal Women With Resected Breast Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: Premenopausal
Sponsor: NCI, Other
Protocol IDs: CDR0000318832, IBCSG-26-02, BIG-4-02, NABCI-IBCSG-26-02, EU-20401, 2005-002626-59, EUDRACT-2005-002626-59, NCT00066807

The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: Postmenopausal
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9238IL/0048, EFECT, D6997C00048, NCT00065325

10.

Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer

Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Status: Closed
Age: 35 and over
Sponsor: Other
Protocol IDs: MAP3, CAN-NCIC-MAP3, PFIZER-EXEAPO-0028-150, ExCel, CDR0000363802, NCT00083174

11.

Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer

Phase: Phase III
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A5991048, NCT00143390

12.

Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane

Phase: Phase III
Type: Treatment
Status: Completed
Age: 50 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 971-ONC-0028-081, A5991026, NCT00036270

13.

Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: Any age
Sponsor: Other
Protocol IDs: CDR0000448616, ICR-CTSU-SOFEA, EU-20531, SSA-04Q200635, ISRCTN44195747, MREC-03677, EUDRACT-2004-000093-30, NCT00253422

14.

Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer

Phase: Phase III
Type: Treatment
Status: Completed
Age: 30 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 96-OEXE-031, A5991012, NCT00038467

15.

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Status: Closed
Age: 18 to 75
Sponsor: NCI
Protocol IDs: NCI-2009-00707, PACCT-1, CDR0000472066, ECOG-PACCT-1, U10CA021115, NCT00310180

16.

Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001Y2301, 2008-008698-69, NCT00863655

17.

Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)

Phase: Phase III
Type: Treatment
Status: Completed
Age: Postmenopausal
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9238UK/0005, NCT00944918

18.

Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen

Phase: Phase III
Type: Treatment
Status: Completed
Age: Postmenopausal
Sponsor: NCI, Other
Protocol IDs: NSABP B-33, CDR0000068640, ECOG-NSABP-B-33, NCT00016432

19.

Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer

Phase: Phase III
Type: Treatment
Status: Completed
Age: Postmenopausal
Sponsor: NCI, Other
Protocol IDs: MA27, CAN-NCIC-MA27, NCCTG-MA27, CALGB-CAN-NCIC-MA27, ECOG-CAN-NCIC-MA27, SWOG-CAN-NCIC-MA27, IBCSG-30-04, EUDRACT-2005-001893-28, CDR0000316325, CAN-NCIC-MA27-COMPANION, NCIC-MA.27, NCT00066573

20.

RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2010-02181, 8539, MCC-8539, CDR0000675612, N01CM00100, NCT01149356

21.

Phase II Study of Exemestane (an Aromatase Inhibitor) for Postmenopausal Women with Advanced Breast Cancer Refractory to Tamoxifen and Megestrol (Summary Last Modified 11/95)

Phase: Phase II
Type: Treatment
Status: Closed
Age: 25 to 90
Sponsor: Other
Protocol IDs: YALE-HIC-7480, NCI-V95-0725

22.

Phase II Study of Exemestane (an Aromatase Inhibitor) for Postmenopausal Women with Metastatic Breast Cancer Refractory to Tamoxifen (Summary Last Modified 10/95)

Phase: Phase II
Type: Treatment
Status: Closed
Age: postmenopausal
Sponsor:
Protocol IDs: YALE-HIC-7437, NCI-V95-0726

23.

Phase II Randomized Study of Exemestane and Raloxifene in Postmenopausal Women With a History of Stage 0 (Ductal Carcinoma in Situ), I, II, or III Breast Cancer Who Have No Clinical Evidence of Disease

Phase: Phase II
Type: Prevention, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-99017, NCI-G99-1662, NCT00004247

24.

Phase II Pilot Study of cDNA Microarray as a Measure of Tumor Response to Neoadjuvant Docetaxel and Capecitabine Followed By Surgery and Adjuvant Doxorubicin and Cyclophosphamide in Patients With Stage II or III Breast Cancer

Phase: Phase II
Type: Diagnostic, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-00-C-0149, NCT00020241

25.

Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000068431, NYU-0004, P-UPJOHN-NYU-0004, NCI-G00-1906, NCT00010010

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map